-
公开(公告)号：US11459395B2
公开(公告)日：2022-10-04
申请号：US17172694
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Ugur Sahin , Friederike Gieseke , Alexander Muik , Christian Grunwitz , Edward Van den Brink , Dennis Verzijl
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20220204636A1
公开(公告)日：2022-06-30
申请号：US17550288
申请日：2021-12-14
Applicant: GENMAB A/S
Inventor： Michel DE WEERS , Tim WALSETH , Jan VAN DE WINKEL , Tom VINK , Paul PARREN
IPC: C07K16/28 , A61K39/395 , A61K45/06 , G01N33/573
Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
-
183.发明申请公开(公告)号：US20220112300A1
公开(公告)日：2022-04-14
申请号：US17558404
申请日：2021-12-21
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Christopher W. L. CHIU , Esther C.W. BREIJ
IPC: C07K16/28 , A61K31/4184 , A61P35/00
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
-
公开(公告)号：US20210324105A1
公开(公告)日：2021-10-21
申请号：US17149019
申请日：2021-01-14
Applicant: GENMAB A/S
Inventor： Bart DE GOEIJ , Patrick VAN BERKEL , Kristin STRUMANE , Aran Frank LABRIJN , Joost J. NEIJSSEN , Joyce I. MEESTERS , Paul PARREN , Janine SCHUURMAN
Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
-
公开(公告)号：US20210317225A1
公开(公告)日：2021-10-14
申请号：US17345628
申请日：2021-06-11
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
Patent Agency Ranking
公开(公告)号：US20210177987A1
公开(公告)日：2021-06-17
申请号：US16760373
申请日：2018-11-01
Applicant: Genmab A/S
Inventor： Reshma Abdulla RANGWALA , Steen LISBY
Abstract: The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).
-
公开(公告)号：US20210163616A1
公开(公告)日：2021-06-03
申请号：US17172694
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20210155699A1
公开(公告)日：2021-05-27
申请号：US17099328
申请日：2020-11-16
Applicant: Genmab A/S
Inventor： Aran Frank LABRIJN , Stefan LOVERIX , Paul PARREN , Jan VAN DE WINKEL , Janine SCHUURMAN , Ignace LASTERS
IPC: C07K16/28 , C07K16/00 , A61K39/395 , A61K51/10 , A61K47/68
Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
-
公开(公告)号：US20210107980A1
公开(公告)日：2021-04-15
申请号：US17053346
申请日：2019-05-07
Applicant: Genmab A/S
Inventor： Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
公开(公告)号：US10968280B2
公开(公告)日：2021-04-06
申请号：US16779011
申请日：2020-01-31
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Ugur Sahin , Friederike Gieseke , Alexander Muik , Christian Grunwitz
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
-
-
-
-
-
-
-
-
Search Results
274
records
(took 0.131 seconds)
